Currently, novel antibodies inhibiting the interaction between SIRPα and CD47 are in preclinical phases, while other anti-CD47 antibodies such as AO-176 are currently under evaluation in clinical trials for the treatments of several types of cancers. The gene discussed is CD47; the disease is cancer.